KPRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KPRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2025-03-15), Kiora Pharmaceuticals's 9-Day RSI is 42.97.
The industry rank for Kiora Pharmaceuticals's 9-Day RSI or its related term are showing as below:
For the Biotechnology subindustry, Kiora Pharmaceuticals's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Kiora Pharmaceuticals's 9-Day RSI falls into.
The formula for calculating RSI is:
RSI | = | 100 | – | [ 100 | / | ( 1 + Average Gain | / | Average Loss )] |
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiora Pharmaceuticals (NAS:KPRX) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Thank you for viewing the detailed overview of Kiora Pharmaceuticals's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.
Carmine N. Stengone | director | 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Aron Shapiro | director | C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452 |
Praveen Tyle | director | ONE BAUSCH & LOMB PLACE, ROCHESTER NY 14604 |
Melissa Tosca | officer: EVP of Finance | C/O KIORA PHARMACEUTICALS, INC., 1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY UT 84105 |
Eric Joseph Daniels | officer: Chief Development Officer | C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452 |
Brian M. Strem | director, officer: President and CEO | C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452 |
Erin Parsons | director | 97 WILLISTON RD, BROOKLINE MA 02445 |
Susan L. Drexler | officer: Interim CFO | 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
David Hollander | director | C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703 |
Armistice Capital Master Fund Ltd. | director, 10 percent owner | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Armistice Capital, Llc | director, 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Steven Boyd | director, 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Kenneth L Gayron | director | 75 NETWORK DRIVE, BURLINGTON MA 34212 |
Franz Obermayr | officer: Acting CEO | C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM MA 02452 |
Thomas Hancock | director | C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110 |
From GuruFocus
By GuruFocus News • 11-13-2024
By ACCESSWIRE ACCESSWIRE • 11-10-2020
By GuruFocus News • 02-15-2025
By [email protected] [email protected] • 06-01-2020
By GuruFocus Research • 02-07-2024
By Marketwired Marketwired • 08-10-2021
By Marketwired Marketwired • 07-26-2021
By GuruFocus News • 11-15-2024
By ACCESSWIRE ACCESSWIRE • 09-08-2020
By GuruFocus News • 02-11-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.